22 6月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
28 5月 2020 by admin in UncategorizedComments resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
07 5月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TPST-1495 CLINICAL STUDY: DUAL EP2/4 ANTAGONIST TARGETING SOLID TUMORS
07 5月 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
07 5月 2020 by admin in UncategorizedComments Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
05 5月 2020 by admin in UncategorizedComments Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
29 4月 2020 by admin in UncategorizedComments resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
13 4月 2020 by admin in UncategorizedComments NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
20 3月 2020 by admin in UncategorizedComments Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders
